Inari Medical, Inc. (NASDAQ:NARI) Receives Consensus Rating of “Hold” from Analysts

Inari Medical, Inc. (NASDAQ:NARI) has been given an average rating of “Hold” by the fourteen ratings firms that are covering the firm, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $68.00.

Several analysts recently commented on NARI shares. BTIG Research reaffirmed a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. Robert W. Baird restated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Piper Sandler increased their target price on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. William Blair restated a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $80.00 price objective (up previously from $65.00) on shares of Inari Medical in a report on Tuesday, January 7th.

Insider Activity at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the transaction, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. This represents a 45.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 263,000 shares of company stock valued at $15,599,470 over the last quarter. Corporate insiders own 10.60% of the company’s stock.

Hedge Funds Weigh In On Inari Medical

Several large investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its holdings in Inari Medical by 128.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock worth $33,000 after acquiring an additional 356 shares during the period. R Squared Ltd bought a new position in shares of Inari Medical in the 4th quarter worth $45,000. Quarry LP acquired a new stake in shares of Inari Medical during the fourth quarter worth $57,000. Quadrant Capital Group LLC increased its holdings in Inari Medical by 12.3% in the fourth quarter. Quadrant Capital Group LLC now owns 1,301 shares of the company’s stock valued at $66,000 after purchasing an additional 143 shares during the last quarter. Finally, KBC Group NV lifted its stake in Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock valued at $73,000 after buying an additional 498 shares during the period. 90.98% of the stock is currently owned by institutional investors and hedge funds.

Inari Medical Price Performance

NASDAQ:NARI opened at $79.97 on Wednesday. Inari Medical has a 12-month low of $36.73 and a 12-month high of $79.99. The firm has a market capitalization of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. The firm has a 50-day moving average price of $74.47 and a 200 day moving average price of $56.87.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.